We are live on ! Find out more
CNTA

Centessa Pharmaceuticals

Delisted

CNTA was delisted on the 23rd of June, 2026.

80 hedge funds and large institutions have $781M invested in Centessa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $119K | Put options by funds: $27K

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

16% more funds holding

Funds holding: 6980 (+11)

0.33% more ownership

Funds ownership: 76.2%76.53% (+0.33%)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

7% less capital invested

Capital invested by funds: $841M → $781M (-$59.5M)

Holders
80
Holders Change
+11
Holders Change %
+15.94%
% of All Funds
1.15%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
17
Increased
27
Reduced
19
Closed
6
Calls
$119K
Puts
$27K
Net Calls
+$92K
Net Calls Change
-$47K
Name Holding Trade Value Shares
Change
Change in
Stake
JF
51
Jump Financial
Illinois
$220K -$80.6K -8,497 -26%
VI
52
Vestcor Inc
New Brunswick, Canada
$183K +$193K +20,300 New
LCM
53
Lynx1 Capital Management
Puerto Rico
$157K
XT
54
XTX Topco
Cayman Islands
$148K +$155K +16,385 New
AI
55
Atria Investments
North Carolina
$145K +$152K +16,018 New
SSA
56
Schonfeld Strategic Advisors
New York
$111K +$117K +12,300 New
FAM
57
Fred Alger Management
New York
$99.3K +$104K +10,993 New
SIM
58
Sandia Investment Management
Massachusetts
$90.3K +$94.8K +10,000 New
QL
59
Quarry LP
New York
$86.8K +$29.5K +3,108 +48%
VEA
60
Virtus ETF Advisers
New York
$82.3K +$86.5K +9,116 New
EC
61
EntryPoint Capital
New York
$73.5K -$14.2K -1,500 -16%
CUAMC
62
China Universal Asset Management Company
China
$61.5K -$38K -4,009 -37%
JP Morgan Chase
63
JP Morgan Chase
New York
$59.3K -$196K -20,697 -76%
Qube Research & Technologies (QRT)
64
Qube Research & Technologies (QRT)
United Kingdom
$31.8K -$51.4K -5,421 -61%
UBS Group
65
UBS Group
Switzerland
$25.4K +$8.83K +931 +50%
Zurich Cantonal Bank
66
Zurich Cantonal Bank
Switzerland
$20.2K -$313 -33 -1%
Mirae Asset Global Investments
67
Mirae Asset Global Investments
South Korea
$15.5K +$16.4K +1,730 New
GI
68
GAMMA Investing
California
$13.2K -$332 -35 -2%
TRCT
69
Tower Research Capital (TRC)
New York
$11.7K +$2.73K +288 +29%
Citigroup
70
Citigroup
New York
$11.1K +$9.71K +1,024 +502%
Royal Bank of Canada
71
Royal Bank of Canada
Ontario, Canada
$10K +$4.75K +501 +81%
ATC
72
Adirondack Trust Company
New York
$8.35K
BTI
73
Blue Trust Inc
Georgia
$8.01K +$6.72K +709 New
GRP
74
Global Retirement Partners
California
$6.32K
Wells Fargo
75
Wells Fargo
California
$4.7K +$4.93K +520 New

CNTA Hedge Fund Activity: Q2 2024 in Review

80 of the 6,928 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2024, worth a combined $781M — down 7.1% from $841M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CNTA positions and 6 closed out — a net gain of 11 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was First Light Asset Management, adding an estimated $16.9M. The largest seller was Point72 Asset Management, cutting an estimated $4.7M.

  • 80 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2024, up from 69 in Q1 2024.
  • Funds reported $781M of Centessa Pharmaceuticals stock for Q2 2024, down 7.1% quarter-over-quarter.
  • 17 funds opened new Centessa Pharmaceuticals positions in Q2 2024 and 6 closed out, a net change of +11 holders.
  • The largest Centessa Pharmaceuticals buyer in Q2 2024 was First Light Asset Management, an estimated $16.9M added.
  • The largest Centessa Pharmaceuticals seller in Q2 2024 was Point72 Asset Management, an estimated $4.7M sold.

Based on aggregated 13F filings for Q2 2024.